GeneNews, Inc. researches and develops proprietary technology related to the treatment of arthritis. The company is headquartered in Canada.

NEL ASA operates as a hydrogen company, which engages in the provision of solutions to produce, store and distribute hydrogen from renewable energy. Its hydrogen solutions cover the value chain from hydrogen production technologies to manufacturing of hydrogen fueling stations. It operates through the following segments: Nel Hydrogen Fueling and Nel Hydrogen Electrolyser. The Nel Hydrogen Fueling segment is involved in manufacturing of hydrogen fueling stations providing fuel cell electric vehicles with the same fast fueling and long range as conventional fossil fuel vehicles. The Nel Hydrogen Electrolyser segment manages a supplier of hydrogen production equipment and plants based on alkaline and water electrolyser technology. The company was founded by Erik Anders Lönneborg and Praveen Sharma in 1927 and is headquartered in Oslo, Norway.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care. The company is developing the Talis One platform, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform.

Incyte Pharmaceuticals, Inc. engages in the provision of biopharmaceutical services. The company is headquartered in Palo Alto, CA.

Decipher Biosciences, Inc. is a commercial-stage precision oncology company which engages in patient care improvement. The Company’s differentiated approach measures the biological activity of a patient’s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to improve therapy selection and accelerate adoption of new therapies into the standard of care. Its novel prostate cancer genomic testing products examine the underlying biology of a patient’s tumor, enabling physicians to select an optimal therapy. The firm’s whole transcriptome analysis of clinical patient samples from its commercial channel and its participation in practice-changing clinical trials has allowed it to build and expand its Decipher GRID database GRID. The company was founded by Elai Davicioni, Timothy J. Triche, Bruce A. Schmidt, and Jonathan D. Buckley and is headquartered in San Diego, CA.

Iverson Genetic Diagnostics provides diagnostic tools to prevent and treat chronic diseases for physicians. It develops genetic tests for disease detection and treatment. The company also provides a warfarin dosing panel that tests for variations in enzymes that can significantly affect warfarin response; and a high-risk HPV panel, a screening test that detects various HPVs. In addition, it offers an MTHFR assay that detects key variants in the metabolism of homocysteine that is associated with coronary artery disease, thrombosis, heart attacks, and strokes. The company was founded in 2006 and is based in Bothell, Washington.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Beijing Jiyin Medical Technology Co., Ltd., established on 2021-12-20, Business scope includes technology development,Technical Services,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Natural science research and experimental development;Medical Research and Experimental Development;medical service.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Medical services and items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

StageZero Life Sciences is a biotech company developing and commercializing blood-based diagnostic tests for early disease detection. The company next-generation test, Aristotle, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on its proprietary mRNA technology platform, which was validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer. StageZero Life Sciences was founded in 1998 and is based in Richmond Hill, Ontario, Canada.

Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology. Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

Vico Therapeutics BV is a company headquartered in Leiden, the Netherlands. The firm develops ribonucleic acid modulating therapies. It was founded in 2019 by Gail Mandel, Josh Mandel-Brehm and Luc Dochez. Micah Mackison is currently the CEO of the company.\nThe company says this about itself: Vico Therapeutics is committed to advancing RNA modulating therapies for patients with severe, genetic neurological disorders. Vico's lead product candidate, VO659, is being developed for Huntington's disease and spinocerebellar ataxia types 3 and 1. Our VICOMER platform designs antisense oligonucleotides for various genetic defects by modulating or editing RNA.

Develops molecular breeding tools and related technologies for crops

Part of QIAGEN NV, QIAGEN Sciences LLC is an American company located in Germantown, MD. The firm manufactures and distributes sample and assay technology products for preanalytical sample preparations.

Vision Pharma Pty Ltd. manufactures pharmaceutical preparations. The company is headquartered in Mt. Pleasant, Australia.